 Edward Stenehjem
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 15 | 2025 | 130 | 5.160 |
Why?
| | Hospitals, Community | 7 | 2023 | 65 | 2.740 |
Why?
| | Anti-Bacterial Agents | 23 | 2025 | 1915 | 2.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 6 | 2015 | 249 | 1.350 |
Why?
| | Staphylococcal Infections | 5 | 2015 | 390 | 1.210 |
Why?
| | Carrier State | 4 | 2015 | 79 | 1.210 |
Why?
| | Cross Infection | 6 | 2020 | 262 | 1.040 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 398 | 1.020 |
Why?
| | Ambulatory Care | 9 | 2023 | 603 | 0.660 |
Why?
| | Sinusitis | 1 | 2023 | 229 | 0.640 |
Why?
| | Hospitalization | 16 | 2024 | 2434 | 0.610 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 70 | 0.560 |
Why?
| | Anti-Infective Agents | 2 | 2018 | 242 | 0.540 |
Why?
| | Influenza Vaccines | 4 | 2023 | 529 | 0.530 |
Why?
| | Health Plan Implementation | 1 | 2018 | 136 | 0.520 |
Why?
| | Nasal Cavity | 2 | 2015 | 62 | 0.470 |
Why?
| | Drug Utilization | 1 | 2016 | 167 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 6 | 2023 | 1358 | 0.460 |
Why?
| | Community-Acquired Infections | 3 | 2017 | 174 | 0.450 |
Why?
| | Humans | 64 | 2025 | 144957 | 0.420 |
Why?
| | Veterans | 3 | 2015 | 1603 | 0.380 |
Why?
| | Population Surveillance | 2 | 2015 | 485 | 0.380 |
Why?
| | Inappropriate Prescribing | 3 | 2023 | 64 | 0.380 |
Why?
| | Asymptomatic Infections | 1 | 2012 | 37 | 0.380 |
Why?
| | Influenza, Human | 3 | 2023 | 617 | 0.370 |
Why?
| | Ventriculostomy | 1 | 2012 | 24 | 0.360 |
Why?
| | Bacteriological Techniques | 1 | 2012 | 68 | 0.350 |
Why?
| | Drug Resistance, Bacterial | 6 | 2020 | 199 | 0.350 |
Why?
| | Utah | 4 | 2024 | 81 | 0.350 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 138 | 0.350 |
Why?
| | Adult | 30 | 2025 | 40506 | 0.340 |
Why?
| | Bacterial Infections | 2 | 2019 | 246 | 0.340 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2012 | 104 | 0.340 |
Why?
| | Central Nervous System Diseases | 1 | 2012 | 74 | 0.340 |
Why?
| | Mycoses | 1 | 2012 | 88 | 0.340 |
Why?
| | Prostheses and Implants | 1 | 2012 | 141 | 0.330 |
Why?
| | Sepsis | 3 | 2024 | 641 | 0.320 |
Why?
| | Gram-Negative Bacterial Infections | 2 | 2025 | 51 | 0.310 |
Why?
| | Immunization, Secondary | 4 | 2022 | 91 | 0.310 |
Why?
| | Emergency Service, Hospital | 11 | 2024 | 2313 | 0.290 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1054 | 0.290 |
Why?
| | Outpatients | 2 | 2023 | 443 | 0.270 |
Why?
| | RNA, Messenger | 7 | 2024 | 2832 | 0.270 |
Why?
| | Idaho | 2 | 2018 | 15 | 0.270 |
Why?
| | Delivery of Health Care | 3 | 2023 | 947 | 0.250 |
Why?
| | United States | 14 | 2023 | 15988 | 0.240 |
Why?
| | Vaccination | 6 | 2024 | 1423 | 0.240 |
Why?
| | Ambulatory Care Facilities | 3 | 2021 | 266 | 0.240 |
Why?
| | Research Design | 2 | 2025 | 1137 | 0.240 |
Why?
| | Middle Aged | 21 | 2025 | 35928 | 0.220 |
Why?
| | Hospitals | 4 | 2023 | 732 | 0.220 |
Why?
| | Candidemia | 1 | 2024 | 15 | 0.220 |
Why?
| | Candida | 1 | 2024 | 44 | 0.220 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 113 | 0.210 |
Why?
| | Aged | 17 | 2025 | 25947 | 0.210 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.210 |
Why?
| | Aged, 80 and over | 9 | 2024 | 8279 | 0.210 |
Why?
| | Bacteremia | 1 | 2025 | 221 | 0.190 |
Why?
| | Hospitals, Veterans | 2 | 2015 | 259 | 0.190 |
Why?
| | Telemedicine | 2 | 2024 | 948 | 0.180 |
Why?
| | Male | 22 | 2025 | 72406 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2023 | 107 | 0.180 |
Why?
| | Female | 22 | 2025 | 78376 | 0.180 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2023 | 157 | 0.180 |
Why?
| | Adolescent | 12 | 2024 | 22453 | 0.160 |
Why?
| | Case-Control Studies | 6 | 2023 | 3608 | 0.160 |
Why?
| | Language | 1 | 2023 | 323 | 0.160 |
Why?
| | Cohort Studies | 3 | 2023 | 5965 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 201 | 0.160 |
Why?
| | Checklist | 2 | 2018 | 108 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2020 | 74 | 0.150 |
Why?
| | Cooperative Behavior | 2 | 2020 | 465 | 0.140 |
Why?
| | Community-Based Participatory Research | 1 | 2020 | 166 | 0.140 |
Why?
| | Vaccines, Combined | 3 | 2023 | 49 | 0.140 |
Why?
| | Risk Factors | 7 | 2024 | 10792 | 0.140 |
Why?
| | Hospital Bed Capacity | 1 | 2018 | 28 | 0.140 |
Why?
| | Immunization | 1 | 2020 | 374 | 0.140 |
Why?
| | Drug Utilization Review | 1 | 2018 | 61 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 428 | 0.130 |
Why?
| | Health Services Research | 1 | 2020 | 396 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2024 | 17101 | 0.130 |
Why?
| | Inservice Training | 1 | 2018 | 117 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 363 | 0.130 |
Why?
| | Cluster Analysis | 1 | 2018 | 521 | 0.120 |
Why?
| | Young Adult | 6 | 2024 | 14126 | 0.120 |
Why?
| | Documentation | 1 | 2018 | 199 | 0.120 |
Why?
| | Pharmacists | 1 | 2018 | 240 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 570 | 0.120 |
Why?
| | Mass Screening | 3 | 2013 | 1348 | 0.110 |
Why?
| | Patient Readmission | 2 | 2021 | 759 | 0.110 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 23 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2019 | 1095 | 0.110 |
Why?
| | Molecular Epidemiology | 1 | 2015 | 73 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1172 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 940 | 0.100 |
Why?
| | Hospital Mortality | 3 | 2023 | 1031 | 0.100 |
Why?
| | Leadership | 1 | 2018 | 409 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 949 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 186 | 0.100 |
Why?
| | Isoniazid | 1 | 2013 | 71 | 0.100 |
Why?
| | Medical Staff, Hospital | 1 | 2013 | 80 | 0.100 |
Why?
| | Prospective Studies | 7 | 2022 | 7997 | 0.100 |
Why?
| | Bacterial Load | 1 | 2012 | 67 | 0.090 |
Why?
| | Georgia | 1 | 2012 | 83 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5872 | 0.090 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2013 | 131 | 0.090 |
Why?
| | Coinfection | 1 | 2013 | 141 | 0.090 |
Why?
| | Infection Control | 1 | 2013 | 172 | 0.090 |
Why?
| | Intensive Care Units | 2 | 2021 | 916 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 220 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2013 | 216 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2017 | 978 | 0.090 |
Why?
| | Nursing Staff, Hospital | 1 | 2013 | 158 | 0.080 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 94 | 0.080 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 265 | 0.080 |
Why?
| | Pneumonia | 1 | 2017 | 631 | 0.080 |
Why?
| | Gram-Negative Bacteria | 1 | 2011 | 81 | 0.080 |
Why?
| | Logistic Models | 3 | 2025 | 2119 | 0.080 |
Why?
| | Tuberculosis | 1 | 2013 | 291 | 0.080 |
Why?
| | Risk | 1 | 2012 | 911 | 0.080 |
Why?
| | Virulence Factors | 1 | 2011 | 174 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2013 | 354 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 1135 | 0.070 |
Why?
| | Administration, Oral | 2 | 2025 | 848 | 0.070 |
Why?
| | Deep Brain Stimulation | 1 | 2012 | 213 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1416 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2947 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1990 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1822 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2883 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2025 | 170 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 7 | 0.050 |
Why?
| | Ethiopia | 2 | 2013 | 44 | 0.050 |
Why?
| | Child, Preschool | 4 | 2023 | 11799 | 0.050 |
Why?
| | Child | 6 | 2023 | 22657 | 0.050 |
Why?
| | Spermine | 1 | 2023 | 29 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2023 | 50 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2024 | 282 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2118 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 367 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1563 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 245 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 966 | 0.050 |
Why?
| | Quality Improvement | 2 | 2025 | 1291 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2023 | 103 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1325 | 0.040 |
Why?
| | Contraindications | 1 | 2020 | 91 | 0.040 |
Why?
| | Seasons | 1 | 2023 | 556 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 187 | 0.040 |
Why?
| | Clindamycin | 1 | 2020 | 14 | 0.040 |
Why?
| | Daptomycin | 1 | 2020 | 18 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 1026 | 0.040 |
Why?
| | Carbapenems | 1 | 2020 | 26 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2020 | 45 | 0.040 |
Why?
| | Doxycycline | 1 | 2020 | 62 | 0.040 |
Why?
| | Cephalosporins | 1 | 2020 | 47 | 0.040 |
Why?
| | Policy | 1 | 2020 | 147 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3676 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1890 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 3154 | 0.030 |
Why?
| | Information Dissemination | 1 | 2020 | 223 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2019 | 285 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 768 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 748 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6053 | 0.030 |
Why?
| | Clinical Audit | 1 | 2015 | 14 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2020 | 693 | 0.030 |
Why?
| | Electronic Mail | 1 | 2015 | 61 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 376 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1077 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2015 | 284 | 0.030 |
Why?
| | Hand Sanitizers | 1 | 2013 | 2 | 0.030 |
Why?
| | Hand Dermatoses | 1 | 2013 | 7 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.030 |
Why?
| | Patient Isolation | 1 | 2013 | 20 | 0.030 |
Why?
| | World Health Organization | 1 | 2013 | 105 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1540 | 0.020 |
Why?
| | Masks | 1 | 2013 | 70 | 0.020 |
Why?
| | Reminder Systems | 1 | 2013 | 141 | 0.020 |
Why?
| | Time Factors | 2 | 2022 | 7183 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.020 |
Why?
| | Neisseria meningitidis | 1 | 2011 | 23 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2013 | 335 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1486 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2011 | 110 | 0.020 |
Why?
| | Immune Evasion | 1 | 2011 | 64 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 110 | 0.020 |
Why?
| | Locomotion | 1 | 2011 | 105 | 0.020 |
Why?
| | Virulence | 1 | 2011 | 280 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7191 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 589 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2013 | 780 | 0.020 |
Why?
| | Critical Illness | 1 | 2015 | 892 | 0.020 |
Why?
| | Rectum | 1 | 1988 | 180 | 0.020 |
Why?
| | Physical Examination | 1 | 1988 | 240 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1186 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2013 | 1099 | 0.010 |
Why?
| | Abdominal Injuries | 1 | 1985 | 127 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 1985 | 316 | 0.010 |
Why?
| | Norway | 1 | 1988 | 45 | 0.000 |
Why?
| | Prognosis | 1 | 1985 | 4293 | 0.000 |
Why?
|
|
Stenehjem's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|